Article: Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
The Journal of antimicrobial chemotherapy
1997 Volume 39 Suppl A, Page(s) 139–143
Abstract: ... with activity against these organisms. Quinupristin/dalfopristin, the first injectable streptogramin antibiotic ... of quinupristin/ dalfopristin against S. aureus bacteraemia, and quinupristin/dalfopristin may also prove useful ... effect. Quinupristin/ dalfopristin is active in vitro against multi-drug-resistant isolates ...
| Abstract | In recent years there has been a dramatic worldwide increase in the prevalence of multiple drug-resistant strains of common Gram-positive bacteria. This highlights the need for a new class of antibiotic with activity against these organisms. Quinupristin/dalfopristin, the first injectable streptogramin antibiotic, has a unique spectrum of activity, encompassing most Gram-positive cocci (including multi-drug-resistant strains), respiratory pathogens and anaerobes, Gram-positive, and a prolonged post-antibiotic effect. Quinupristin/ dalfopristin is active in vitro against multi-drug-resistant isolates of Staphylococcus aureus, coagulase-negative staphylococci, penicillin-resistant pneumococci and vancomycin-resistant Enterococcus faecium. Clinical case reports have shown that the combination is active against intra-abdominal, aortic graft, bacteraemia and hydrocephalus shunt infections caused by multi-drug-resistant enterococci, particularly E. faecium. In almost all of these clinical situations the enterococcal infection had displayed resistance to all other antimicrobial therapies. Preliminary clinical data have demonstrated the activity of quinupristin/ dalfopristin against S. aureus bacteraemia, and quinupristin/dalfopristin may also prove useful in the treatment of pneumococcal infections. Thus, possible future applications of the combination include the treatment of multi-drug-resistant strains of staphylococci, streptococci and enterococci. Quinupristin/dalfopristin may prove useful in the treatment of staphylococcal infections in children, invasive systemic pneumococcal infections, and nosocomial and community-acquired Gram-positive infections in patients unable to tolerate beta-lactam antimicrobial agents or glycopeptide antibiotics. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MeSH term(s) | Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/therapeutic use ; Coagulase/metabolism ; Drug Resistance, Multiple ; Enterococcus/drug effects ; Gram-Positive Bacteria/drug effects ; Gram-Positive Bacterial Infections/drug therapy ; Humans ; Methicillin Resistance ; Staphylococcus/drug effects ; Streptococcus/drug effects ; Virginiamycin/administration & dosage ; Virginiamycin/therapeutic use | ||||||||||
| Chemical Substances | Anti-Bacterial Agents ; Coagulase ; Virginiamycin (11006-76-1) ; quinupristin-dalfopristin (126602-89-9) | ||||||||||
| Language | English | ||||||||||
| Publishing date | 1997-05 | ||||||||||
| Publishing country | England | ||||||||||
| Document type | Journal Article ; Review | ||||||||||
| ZDB-ID | 191709-2 | ||||||||||
| ISSN | 1460-2091 ; 0305-7453 | ||||||||||
| ISSN (online) | 1460-2091 | ||||||||||
| ISSN | 0305-7453 | ||||||||||
| DOI | 10.1093/jac/39.suppl_1.139 | ||||||||||
| Shelf mark |
|
||||||||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1197: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 124: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.